1350 views4 min read
Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference
VANCOUVER, British Columbia, Jan. 04, 2022 -- Bright Minds Biosciences (βBright Minds,β βBMBβ or the βCompanyβ) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, and ... Read More...